AnaCardio Patents

Patent portfolio assigned to AnaCardio (verified via public assignee records). Estimated patent count: 2. AnaCardio AB - clinical-stage Swedish biopharma (founded 2017 from Karolinska Institutet, Prof. Lars Lund) developing AC01, a first-in-class oral ghrelin-mimetic calcium-sensitizing inotrope for heart failure (HFrEF). Confirmed patents: US patent (No. 12,569,476, protection to ~2042) and a granted European patent for AC01, co-owned with Helsinn Healthcare SA. patent_count_estimate=2 reflects the two confirmed grants (US + EU); exact total family size not enumerated. No public competitors/customers applicable (pre-commercial drug developer).